JPH03503522A - 溶菌ペプチドによる真核性病原体と新生物の抑制及び線維芽細胞とリンパ球の刺激 - Google Patents
溶菌ペプチドによる真核性病原体と新生物の抑制及び線維芽細胞とリンパ球の刺激Info
- Publication number
- JPH03503522A JPH03503522A JP63506420A JP50642088A JPH03503522A JP H03503522 A JPH03503522 A JP H03503522A JP 63506420 A JP63506420 A JP 63506420A JP 50642088 A JP50642088 A JP 50642088A JP H03503522 A JPH03503522 A JP H03503522A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- peptide
- cecropin
- raytech
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 73
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 34
- 230000000638 stimulation Effects 0.000 title claims abstract description 19
- 244000052769 pathogen Species 0.000 title claims abstract description 16
- 210000002950 fibroblast Anatomy 0.000 title claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 12
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 12
- 230000005764 inhibitory process Effects 0.000 title abstract description 6
- 230000002101 lytic effect Effects 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 claims abstract description 140
- 108050004290 Cecropin Proteins 0.000 claims abstract description 69
- 241000894006 Bacteria Species 0.000 claims abstract description 24
- 244000005700 microbiome Species 0.000 claims abstract description 21
- 230000003834 intracellular effect Effects 0.000 claims abstract description 18
- 230000035755 proliferation Effects 0.000 claims abstract description 15
- 241000700605 Viruses Species 0.000 claims abstract description 10
- 238000000338 in vitro Methods 0.000 claims abstract description 10
- 206010025323 Lymphomas Diseases 0.000 claims abstract description 8
- 238000001727 in vivo Methods 0.000 claims abstract description 7
- 208000032839 leukemia Diseases 0.000 claims abstract description 6
- 230000000694 effects Effects 0.000 claims description 54
- 150000001413 amino acids Chemical class 0.000 claims description 43
- 241001465754 Metazoa Species 0.000 claims description 26
- 208000015181 infectious disease Diseases 0.000 claims description 24
- 230000012010 growth Effects 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 10
- 230000002209 hydrophobic effect Effects 0.000 claims description 9
- 230000001629 suppression Effects 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 244000000010 microbial pathogen Species 0.000 claims description 8
- 230000000844 anti-bacterial effect Effects 0.000 claims description 7
- 230000005660 hydrophilic surface Effects 0.000 claims description 7
- 241000233866 Fungi Species 0.000 claims description 6
- 230000015556 catabolic process Effects 0.000 claims description 6
- 238000006731 degradation reaction Methods 0.000 claims description 6
- 230000005540 biological transmission Effects 0.000 claims description 5
- 230000006870 function Effects 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 235000013405 beer Nutrition 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 230000005661 hydrophobic surface Effects 0.000 claims description 3
- 230000001086 cytosolic effect Effects 0.000 claims description 2
- 201000008585 noma Diseases 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 241000554826 Deima Species 0.000 claims 1
- 241000186781 Listeria Species 0.000 claims 1
- 241001543835 Neoporus Species 0.000 claims 1
- 206010042135 Stomatitis necrotising Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000010267 cellular communication Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 20
- 230000004936 stimulating effect Effects 0.000 abstract description 4
- 206010001935 American trypanosomiasis Diseases 0.000 abstract description 3
- 241000223109 Trypanosoma cruzi Species 0.000 abstract description 3
- 102000016943 Muramidase Human genes 0.000 abstract description 2
- 108010014251 Muramidase Proteins 0.000 abstract description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 abstract description 2
- 229960000274 lysozyme Drugs 0.000 abstract description 2
- 235000010335 lysozyme Nutrition 0.000 abstract description 2
- 239000004325 lysozyme Substances 0.000 abstract description 2
- 241000223960 Plasmodium falciparum Species 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 33
- 229940024606 amino acid Drugs 0.000 description 33
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 210000004379 membrane Anatomy 0.000 description 15
- 239000012528 membrane Substances 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 12
- 108700022013 Insecta cecropin B Proteins 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 241000238631 Hexapoda Species 0.000 description 8
- 244000052616 bacterial pathogen Species 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 229920000126 latex Polymers 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 210000003501 vero cell Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 244000166124 Eucalyptus globulus Species 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 239000008380 degradant Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000000230 African Trypanosomiasis Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000024699 Chagas disease Diseases 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 244000205754 Colocasia esculenta Species 0.000 description 2
- 235000006481 Colocasia esculenta Nutrition 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 241000981595 Zoysia japonica Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 210000005256 gram-negative cell Anatomy 0.000 description 2
- 208000029080 human African trypanosomiasis Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 244000000003 plant pathogen Species 0.000 description 2
- 235000013930 proline Nutrition 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 201000002612 sleeping sickness Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- GHIVDTCFLFLOBV-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-acetyloxybenzoate Chemical compound CCN(CC)CCOC(=O)C1=CC=CC=C1OC(C)=O GHIVDTCFLFLOBV-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 101710086289 Attacin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 101800003223 Cecropin-A Proteins 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 101000957815 Culex pipiens Alpha-glucosidase Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- 241001067739 Lotis Species 0.000 description 1
- 206010025280 Lymphocytosis Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101100276984 Mus musculus Ccdc88c gene Proteins 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000588701 Pectobacterium carotovorum Species 0.000 description 1
- 240000007643 Phytolacca americana Species 0.000 description 1
- 235000009074 Phytolacca americana Nutrition 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241001648319 Toronia toru Species 0.000 description 1
- 244000178289 Verbascum thapsus Species 0.000 description 1
- 235000010599 Verbascum thapsus Nutrition 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001420 bacteriolytic effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- HCQPHKMLKXOJSR-IRCPFGJUSA-N cecropin-a Chemical group C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(N)=O)[C@@H](C)CC)C(C)C)[C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCCN)C1=CC=CC=C1 HCQPHKMLKXOJSR-IRCPFGJUSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006367 cytoskeletal formation Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 201000003373 familial cold autoinflammatory syndrome 3 Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000005255 gram-positive cell Anatomy 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 108010046119 hemolin Proteins 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- XMHIUKTWLZUKEX-UHFFFAOYSA-N hexacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O XMHIUKTWLZUKEX-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- ZLIBICFPKPWGIZ-UHFFFAOYSA-N pyrimethanil Chemical compound CC1=CC(C)=NC(NC=2C=CC=CC=2)=N1 ZLIBICFPKPWGIZ-UHFFFAOYSA-N 0.000 description 1
- VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Insects & Arthropods (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (44)
- 1.次のようなレイシングユウカリオテック細胞の学問体系。 セイデックペプタイドと細胞の連結、分解の影響をあたえる細胞、ここにのべた ごとくユウカリオテック微生物の本質からえらばれた細胞、レイムフォマス、ル キミイア及びカシィノマスとユウカリオテック細胞伝染とイントラセレラ病原菌 微生物。 ここにのべたごとくペプタイド成立は、約30から40程のアミノ酸少なくとも 部分的には、アムフィフィリックα−ヘリカル構成でなっており、事実のハイド ロフィリックの頭と積極的な濃度大要のハイドロブイビックの尾、優勢のハイド ロフィアビツク表面の長さの構成、そして優勢のハイドロフィリック表面に対抗 する。
- 2.次のようなレイシングユウカリオテック細胞の選択性。 ターゲットユウカリオテック細胞の存在とナン・ターゲット細胞と選択性のレイ ス・ターゲット細胞;ここに、ターゲット細胞は、グループの中からえらばれ、 ユウカリオテック微生物の本質から成っている。 レイムフォマス、ルキミア、カーシイノマ、そしてユウカロテック細胞感染とイ ントラセルラ病原菌微生物; ここでは、ペプタイドコンブライズ30から40のアミノ酸、少なくとも部分的 にアムフィフィリックα−ヘリイカルの構成。
- 3.次のようなレイシングユウカリオテック微生物の体系。 ユウカロティックとレイテックペプタイドの十分な影きょうライシイスについて 、ユウカリオテック、約30と40程のアミノ酸から成立されており、少なくと も部分はアムフィフィリックα−ヘリカル構成。
- 4.次のごときレイシング哺乳動物ガン細胞の体系。 レイムフォマー、白血病又はカアシイノマ細胞と効果的なレイテックペプタイド とレイスの細胞、ペプタイド成立は、30から40のアミノ酸から成り立ってお り、少なくとも部分は、アムフィパシィックα−ヘリイカル構成。
- 5.次のごとき選択性のあるレイシング感染ユウカリオテック細胞の体系。 ユウカリオテック細胞の感染と、イントラセルラ病原菌徴生物無感染ユウカリオ テック細胞の存在と選択性レイテック、フリーペプタイドの影きょう感染細胞。
- 6.請求項1、2又は5の体系で、ここにイントラセルラ病原菌微生物はビール ス、バクテリア、ファンギとプロトザのグループから選ばられるもの。
- 7.請求項6の体系でイントラセルラ;病原菌はDNAビールスであるもの。
- 8.請求項6の体系で、ビールスパライソフルエンザマースレス又はハーベスシ ンプレックIIであるもの。
- 9.請求項6の体系で、バクテリアはリステリア又はビルセラの類のもの。
- 10.請求項6の体系で、イントラセルラ病原歯はタイパノソマ又はパスモディ ウムのもの。
- 11.請求項5の体系、レイテック、ペプタイドは約30から40のアミノ酸か ら成立しており、少なくとも部分はアムフィフィリックα−ヘリカル構成のもの 。
- 12.請求項2、3、4又は11の体系で、ペプタイドは大要はハイドロフィリ ック頭とポジイティブ、チャージ濃度、大要のハイドロホビック尾は、優勢のハ イドロフィリック表面にそっての長さの構成、優勢のハイドロフィブ表面に対す るもの。
- 13.請求項1、2、3、4、又5の体系で、サイトプラスミックの発見、ライ シイド細胞から生産されるもの。
- 14.請求項1、2、又3、体系で、ユウカリオテック微生物は、プロトザアと ファンギの本質から成立この仲間から選択されるもの。
- 15.請求項14の体系で、微生物はタイパノソマ又はプラスマジウムの類に入 るもの。
- 16.請求項14の体系で、微生物はイーストであるもの。
- 17.請求項1、2、3、4、又5の体系で、高等動物に効果的で連結するもの 。
- 18.請求項1、2、3、4、又5の体系で、レイテックペプタイドはセクロピ ンかサアコトクシンであるもの。
- 19.ユウカリオデック細胞の高等動物についての抑制であって、選択性レイテ ックの紹介、フリーペプタイドの高等動物が抑制の効果、ユウカリオテック細胞 はえらびユウカリオテック微生物、リンフォマス、ルキミア、カシイノマのグル ープから、そして、イントラセルラ病原菌微虫物の感染細胞。
- 20.請求項19の体系で、高等動物は、コーラデイト動物又はナンコーラデイ ト農業、動物であるもの。
- 21.請求項19でペプタイドは30から40のアミノ酸から成立少なくとも部 分はアムフィフィリックα−ヘリカル構成、大要のハイドロフィリック頭の積極 性濃度、大要のハイドロブイビック尾、優勢ハイドロブイリック表面の長さにそ っての構成、優勢のハイドロフォビツク表面の対立したもの。
- 22.請求項19の体系で、レイテックペプタイドはセクロピン又はサアコテッ クスであるもの。
- 23.請求項19の体系で、ペプタイドはセクロピンであるもの。
- 24.請求項19の体系で、ペプタイドはシイーバ1であるもの。
- 25.ユウカリオテック微生物の抑制の高等動物において、レイテック選択の紹 介、フリーペプタイドが高等動物の中での抑制感染とユウカロテックと抑制の感 染であるもの。
- 26.請求項25の体系で、客体はコーラディト動物でであるもの。
- 27.請求項25の体系。
- 28.請求項26の体系で、次のレィテック、ペプタイドの成立したもの。 (a)30から40アミノ酸、少なくとも部分的にαヘリックで成立している。 (b)大要ハイドロフィリック頭の積極性濃度;(c)大要のハイドロホビック 尾; (d)第1優勢、ハイドロホビック表面にそっての長さ、ヘリック; (e)第2優勢ハイドロホリック表面に反する第1の表面体。
- 29.請求項25の体系で、レイテックペプタイドは、セクロピンとサアコテッ クスインの本質により、仲間からえらばれるもの。
- 30.請求項25の体系で、感染オーガニズムはファンギーとプロトドアンの本 質により選択されるもの。
- 31.請求項25の体系、感染オーガニズムは、サーコディナ;マシィティゴホ ラシリアタとスポロザから成立しておりえらばれるもの。
- 32.哺乳動物における抑制ガン細胞の体系で選択力のあるレイテックの紹介、 フリーペプタイドが哺乳動物に入りこむ、レンファモア、ルキミア、又カーシイ ノマ細胞の抑制の効果のあるもの。
- 33.請求項1、2、3、4、5、19、25、32の体系で、レイテックペプ タイドはアドミクスチュアとレイソデイマのサイノレジィステックブロブーショ ンであるもの。
- 34.正常な哺乳動物ファイブロブラストとレインフォシイテックの増殖の刺激 ファブロブラスト又はレイフォサイテスとレイテックペプタイドがおよぼす増殖 の刺激。
- 35.請求項34の体系で、ファイブロブラスト又はレイムフォサイテスからの 生物学的生産のもの。
- 36.哺乳動物において正常なファイブロブラストとリムフォサイテスの増殖の 刺激で、ファイブロラスト又はレイムフォサイテスの増殖の刺激、哺乳動物に入 りこむレイデイスペプタイドの紹介のもの。
- 37.請求項20、26、32、又36の体系で1から約200マイクロモラー からペプタイドのセウムコンセントレイションの十分な供給のもの。
- 38.請求項37体系で50から約200マイクロモラーのペプタイド、セルム のもの。
- 39.請求項37体系で1から約100mg/Kgの量のもの。
- 40.レイテックペプタイドはアミノ酸のシイバ1から本質が作られている。
- 41.レイテックペプタイドはセクロピンSB−37、アミノ酸類の本質を持っ ている。
- 42.実験事実の組立て、レイテック・ペプタイドとレインズミはサイナジイス テックブロブーション、バクテリアの抑制の含有物。
- 43.請求項42でその他のファーマセクティカル、キャリア。
- 44.請求項42でレイデックペプタイドはセクロピンとサアーコテクシンの本 質から成りグループから選ばれるもの。 セクロピン途サアユトクシンのようなレイテックペプタイドとファブロブラスト 、レイフォサイテスの刺激とネオポラスとユウカロイテック病原菌の抑制、ユウ カロイテック細胞はセクロピンとサアコトクシンと連絡している。シイナシイス テック結合とセクロピン又はサアコトクシインとレイソウゾウム、分解の影響又 は抑制と細胞ターゲット細胞ユウカロイテック微生物、プロトマザアのようなも のを含む、T.クルズイとP.フアルシイパルム、哺乳動物とルキミア、及び細 胞感染とイントラセルラ病原菌、ビールスのようなバクテリアとプロトロザ、尚 、発表は、リムフォサイテス、ファイブロブラスの増殖刺激及びサクロビン又は サーコトクシンの効果と細胞の連絡。メリットは、インビィトロ又はインビイボ 。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6965387A | 1987-07-06 | 1987-07-06 | |
US069,653 | 1987-07-06 | ||
US10217587A | 1987-09-29 | 1987-09-29 | |
US102,175 | 1987-09-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH03503522A true JPH03503522A (ja) | 1991-08-08 |
JP2962555B2 JP2962555B2 (ja) | 1999-10-12 |
Family
ID=26750283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP63506420A Expired - Lifetime JP2962555B2 (ja) | 1987-07-06 | 1988-07-06 | 溶菌ペプチドによる真核性病原体と新生物の抑制及び繊維芽細胞とリンパ球の刺激 |
Country Status (8)
Country | Link |
---|---|
US (2) | US5962410A (ja) |
EP (1) | EP0383770B1 (ja) |
JP (1) | JP2962555B2 (ja) |
KR (1) | KR970006154B1 (ja) |
AT (1) | ATE127838T1 (ja) |
AU (1) | AU2132088A (ja) |
DE (1) | DE3854476T2 (ja) |
WO (1) | WO1989000194A1 (ja) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861478A (en) * | 1987-07-06 | 1999-01-19 | Helix Biomedix, Inc. | Lytic peptides |
WO1990012866A1 (en) * | 1989-04-10 | 1990-11-01 | Louisiana State University And Agricultural And Mechanical College | Lytic peptides, use for growth, infection and cancer |
CA2043463A1 (en) * | 1990-06-13 | 1991-12-14 | Nancy L. Bycroft | Synergistic antimicrobial compositions |
AU648140B2 (en) * | 1991-02-01 | 1994-04-14 | Virtual Drug Development, Inc. | Reverse antimicrobial peptides and antimicrobial compositions |
JPH07102131B2 (ja) * | 1991-07-15 | 1995-11-08 | 日本石油株式会社 | ヒトリンパ球の癌細胞に対する傷害活性を高める方法 |
US5850025A (en) * | 1991-09-19 | 1998-12-15 | Sibia Neurosciences, Inc. | Protection of plants against plant pathogens |
US5422108A (en) * | 1991-09-19 | 1995-06-06 | Smart Plants International Inc. | Protection of plants against plant pathogens |
DE69233410D1 (de) * | 1991-10-04 | 2004-10-21 | Univ North Carolina State | Pathogenresistente transgene pflanzen |
US6008436A (en) * | 1993-01-21 | 1999-12-28 | North Carolina State University | Nematode-resistant transgenic plants |
US5968904A (en) * | 1993-06-04 | 1999-10-19 | Demegen, Inc. | Modified arginine containing lytic peptides and method of making the same by glyoxylation |
US6156568A (en) * | 1993-06-30 | 2000-12-05 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Transformed eukaryotic cells |
US5548075A (en) * | 1993-08-30 | 1996-08-20 | Utah State University | DNA cassette and transgenic organisms carrying lytic peptide-encoding genes |
US5856178A (en) * | 1993-08-30 | 1999-01-05 | Utah State University | DNA cassettes for expression of lytic peptides in mammalian cells and transgenic organisms containing same |
DK0817858T3 (da) * | 1995-03-09 | 2003-08-11 | Gsf Forschungszentrum Umwelt | Vektorer, som indeholder terapeutiske gener for antimikrobielle peptider, til anvendelse ved genterapi |
AU6111396A (en) * | 1995-06-07 | 1996-12-30 | Utah State University | Dna cassettes for expression of lytic peptides in mammalian cells and transgenic organisms containing same |
US6635740B1 (en) * | 1997-03-27 | 2003-10-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Ligand/lytic peptide compositions and methods of use |
HU221407B1 (hu) | 1997-03-28 | 2002-09-28 | Gyula Magvasi | Ektodermális eredetû szövetekben fellépõ tumoros burjánzást gátló hatóanyag és készítmény, valamint eljárás elõállításukra |
US8283315B2 (en) | 1998-08-28 | 2012-10-09 | Lytix Biopharma As | Inhibition of tumour growth |
GB0605685D0 (en) * | 2006-03-21 | 2006-05-03 | Lytix Biopharma As | Inhibition of tumour growth |
US6451365B1 (en) | 2000-07-14 | 2002-09-17 | Rhodia Inc. | Antibacterial composition for control of gram positive bacteria in food applications |
AU6609900A (en) * | 1999-07-30 | 2001-02-19 | The Texas A & M University System | Antibiotics based upon bacteriophage lysis proteins |
US6875744B2 (en) * | 2001-03-28 | 2005-04-05 | Helix Biomedix, Inc. | Short bioactive peptides |
EP1379265A4 (en) * | 2001-03-28 | 2005-09-14 | Helix Biomedix Inc | SHORT BIOACTIVE PEPTIDES AND METHODS OF USE |
US20050209157A1 (en) * | 2001-03-28 | 2005-09-22 | Owen Donald R | Short bioactive peptides and methods for their use |
DE60329382D1 (de) * | 2002-04-22 | 2009-11-05 | Dow Global Technologies Inc | Kostengünstige herstellung von peptiden |
US20040235011A1 (en) * | 2002-06-26 | 2004-11-25 | Cooper Richard K. | Production of multimeric proteins |
US20040172667A1 (en) | 2002-06-26 | 2004-09-02 | Cooper Richard K. | Administration of transposon-based vectors to reproductive organs |
US7527966B2 (en) | 2002-06-26 | 2009-05-05 | Transgenrx, Inc. | Gene regulation in transgenic animals using a transposon-based vector |
CA2493227A1 (en) * | 2002-07-23 | 2004-01-29 | Biogal Gyogyszergyar Rt. | Preparation of 1h-imidazo[4,5-c]quinolin-4-amines via1h-imidazo [4,5-c]quinolin-4-phthalimide intermediates |
US8071364B2 (en) | 2003-12-24 | 2011-12-06 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
US20050282755A1 (en) * | 2004-03-18 | 2005-12-22 | Ansata Therapeutics, Inc. | Compositions having antimicrobial activity and uses thereof |
US7354888B2 (en) | 2004-11-10 | 2008-04-08 | Danisco A/S | Antibacterial composition and methods thereof comprising a ternary builder mixture |
JP5335241B2 (ja) * | 2005-02-09 | 2013-11-06 | ヘリックス バイオメディックス インコーポレイテッド | 抗微生物ヘキサペプチド |
EP2125878B1 (en) | 2007-01-05 | 2013-02-20 | Helix Biomedix, Inc. | Short bio-active peptides for cellular and immunological modulation |
JP5616233B2 (ja) * | 2008-01-24 | 2014-10-29 | エスペランス ファーマシューティカルズEsperance Pharmaceuticals | 溶解ドメイン融合コンストラクト及びその生成及び使用方法 |
GB0815484D0 (en) | 2008-08-26 | 2008-10-01 | Univ Leuven Kath | Antibacterial agents |
US9150880B2 (en) | 2008-09-25 | 2015-10-06 | Proteovec Holding, L.L.C. | Vectors for production of antibodies |
US9157097B2 (en) | 2008-09-25 | 2015-10-13 | Proteovec Holding, L.L.C. | Vectors for production of growth hormone |
WO2010118360A1 (en) | 2009-04-09 | 2010-10-14 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Production of proteins using transposon-based vectors |
WO2010149795A1 (en) | 2009-06-26 | 2010-12-29 | Lysando Holding Establishment | Antimicrobial agents |
ES2579806T3 (es) | 2009-06-26 | 2016-08-16 | Katholieke Universiteit Leuven, K.U. Leuven R&D | Agentes antimicrobianos |
EP2468856A1 (en) * | 2010-12-23 | 2012-06-27 | Lysando Aktiengesellschaft | Antimicrobial Agents |
AU2013337926B2 (en) | 2012-10-30 | 2017-12-21 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
SI2956155T1 (sl) | 2013-02-14 | 2017-10-30 | Helix Biomedix Inc. | Kratki bio aktivni peptidi za spodbujanje celjenja ran |
EP3206704B1 (en) | 2014-10-14 | 2022-04-20 | Riptide Bioscience, Inc. | Peptides having anti-inflammatory properties |
US11124605B2 (en) | 2015-06-26 | 2021-09-21 | The Board Of Trustees Of The University Of Illinois | Antimicrobial alpha-helical cationic polypeptides |
WO2018140613A1 (en) | 2017-01-25 | 2018-08-02 | The Board Of Trustees Of The University Of Illinois | Conformation switchable antimicrobial peptides and methods of using the same |
US10413584B1 (en) | 2018-08-29 | 2019-09-17 | Riptide Bioscience, Inc. | Peptides having immunomodulatory properties |
US10548944B1 (en) | 2018-10-19 | 2020-02-04 | Riptide Bioscience, Inc. | Antimicrobial peptides and methods of using the same |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB145338A (en) | 1919-11-12 | 1920-07-02 | Thomas Allan | Improvements in micrometer indicators for journal bearings |
US4704362A (en) * | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
US4355104A (en) * | 1980-06-17 | 1982-10-19 | Kabigen Ab | Bacteriolytic proteins |
US4520016A (en) * | 1980-06-17 | 1985-05-28 | Kabigen Ab | Bacteriolytic proteins |
WO1982003872A1 (en) * | 1981-04-27 | 1982-11-11 | Washington Univ | B.thuringiensis crystal protein in e.coli |
US4579821A (en) * | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
NZ210093A (en) * | 1983-11-18 | 1988-11-29 | Lubrizol Genetics Inc | Genetic modification of plant cells by octopine t-dna promoters and/or polyadenylation sites; dna vectors, bacterial strains and plant tissue |
US4751081A (en) * | 1984-03-26 | 1988-06-14 | Advanced Genetic Sciences, Inc. | Chitinase-producing bacteria |
US4643988A (en) * | 1984-05-15 | 1987-02-17 | Research Corporation | Amphipathic peptides |
EP0184288A1 (en) * | 1984-10-23 | 1986-06-11 | Schering Agrochemicals Limited | Herbicides, insecticides and fungicides |
JPS61122299A (ja) * | 1984-11-19 | 1986-06-10 | Wakunaga Seiyaku Kk | 抗菌性ポリペプチド、その製造法およびその用途 |
US5206154A (en) * | 1985-01-28 | 1993-04-27 | Xoma Corporation | Method of producing cecropins by microbiological techniques |
KR870700095A (ko) * | 1985-01-28 | 1987-02-28 | 원본미기재 | AraB 프로모터 및 미생물학적 방법에 의해 세크로핀을 포함한 폴리펩타이드를 제조하는 방법 |
EP0590301A2 (en) * | 1986-07-25 | 1994-04-06 | Louisiana State University and Agricultural and Mechanical College | Method for protecting plants from disease and infestation by gene insertion, and vectors and plant cells containing said genes |
US5597945A (en) | 1986-07-25 | 1997-01-28 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Plants genetically enhanced for disease resistance |
CA1327311C (en) * | 1987-07-06 | 1994-03-01 | Jesse M. Jaynes | Therapeutic antimicrobial polypeptides, their use and methods for preparation |
AU2802989A (en) * | 1987-11-02 | 1989-06-01 | Louisiana State University Agricultural And Mechanical College | Plants genetically enhanced for disease resistance |
US5045531A (en) * | 1989-12-18 | 1991-09-03 | Magainin Sciences Inc. | Wound treatment employing biologically active ion channel forming peptides and proteins |
US5208220A (en) * | 1990-06-27 | 1993-05-04 | Magainin Pharmaceuticals, Inc. | Composition and treatment with biologically active peptides and antibiotics which inhibit DNA gyrase |
US5561107A (en) * | 1993-06-04 | 1996-10-01 | Demeter Biotechnologies, Ltd. | Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides |
US5773413A (en) * | 1993-06-04 | 1998-06-30 | Demeter Biotechnologies, Ltd. | Method of combating mammalian neoplasias, and lytic peptides therefor |
WO1995001095A1 (en) * | 1993-06-30 | 1995-01-12 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Transformed eukaryotic cells, and transposon-based transformation vectors |
US5548075A (en) * | 1993-08-30 | 1996-08-20 | Utah State University | DNA cassette and transgenic organisms carrying lytic peptide-encoding genes |
-
1988
- 1988-07-06 KR KR1019890700405A patent/KR970006154B1/ko not_active IP Right Cessation
- 1988-07-06 AU AU21320/88A patent/AU2132088A/en not_active Abandoned
- 1988-07-06 EP EP88906595A patent/EP0383770B1/en not_active Expired - Lifetime
- 1988-07-06 JP JP63506420A patent/JP2962555B2/ja not_active Expired - Lifetime
- 1988-07-06 WO PCT/US1988/002272 patent/WO1989000194A1/en active IP Right Grant
- 1988-07-06 DE DE3854476T patent/DE3854476T2/de not_active Expired - Lifetime
- 1988-07-06 AT AT88906595T patent/ATE127838T1/de not_active IP Right Cessation
-
1994
- 1994-09-06 US US08/301,733 patent/US5962410A/en not_active Expired - Lifetime
-
1999
- 1999-10-04 US US09/411,968 patent/US6440935B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1989000194A1 (en) | 1989-01-12 |
KR890701722A (ko) | 1989-12-21 |
US5962410A (en) | 1999-10-05 |
DE3854476D1 (de) | 1995-10-19 |
KR970006154B1 (ko) | 1997-04-24 |
US6440935B1 (en) | 2002-08-27 |
AU2132088A (en) | 1989-01-30 |
EP0383770A1 (en) | 1990-08-29 |
EP0383770B1 (en) | 1995-09-13 |
JP2962555B2 (ja) | 1999-10-12 |
DE3854476T2 (de) | 1996-04-04 |
EP0383770A4 (en) | 1991-08-14 |
ATE127838T1 (de) | 1995-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH03503522A (ja) | 溶菌ペプチドによる真核性病原体と新生物の抑制及び線維芽細胞とリンパ球の刺激 | |
Li et al. | Roles of d-amino acids on the bioactivity of host defense peptides | |
EP1004595B1 (en) | Lytic and proliferative peptides and their use as pharmaceutic and phytopharmaceutic agents | |
JP6655626B2 (ja) | 新規な免疫原性ペプチド | |
US5428016A (en) | Antimicrobial peptide and antimicrobial agent | |
JP6040212B2 (ja) | 組換えマンネンタケ(Ganodermalucidium)免疫調節タンパク質(rLZ−8)およびその使用 | |
US6255282B1 (en) | Lytic peptides | |
Citarasu et al. | Isolation of Aeromonas hydrophila from infected ornamental fish hatchery during massive disease outbreak | |
Qi et al. | Gemini peptide amphiphiles with broad-spectrum antimicrobial activity and potent antibiofilm capacity | |
CN105061603B (zh) | 抗菌肽-溶菌酶融合蛋白的制备方法及其应用 | |
CN109069605A (zh) | 新免疫原性CD1d结合肽 | |
JPH05504566A (ja) | 生物学的活性を有するペプチドを使用した創傷処置方法 | |
TWI328038B (en) | Fungal immunomodulatory protein (fip) prepared by microorganisms and uses thereof | |
CN106659748A (zh) | 不动杆菌属溶素 | |
CN106715468A (zh) | 用于癌症靶向治疗的包含基于重组血红蛋白蛋白质或亚基的治疗剂的药物组合物 | |
CN107252475B (zh) | 天然宿主防御肽Alligatorin4的应用 | |
CN104717970A (zh) | 提高谷胱甘肽的组合物及其用途 | |
CN105085647B (zh) | 天然抗感染抗氧化双功能肽Pb-CATH2及其基因与应用 | |
Lehrer et al. | Biochemistry and function of monocytes and macrophages | |
CN109628460A (zh) | 一种超深渊来源抗菌肽hydramacin及其制备方法 | |
CN109517046B (zh) | 一种基于外膜蛋白生成机制的抗菌多肽及其应用 | |
CN101420973A (zh) | 包含SODs和基于谷醇溶蛋白的肽片段的药物组份 | |
CN109824761A (zh) | 低溶血抗菌肽BmKn2-7K及其应用 | |
CN113480630B (zh) | 一种长翼蝠来源抗菌肽ms-cath及其应用 | |
Bindiya et al. | Bacteriocins BaCf3 and BpSl14 with anticancer and antibiofilm potential from probiotic Bacillus amyloliquefaciens BTSS3 and Bacillus pumilus SDG14 isolated from gut of marine fishes: Enhanced production, Purification and Characterization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070806 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080806 Year of fee payment: 9 |
|
EXPY | Cancellation because of completion of term |